Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Nektar Therapeutics

Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and viral diseases. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates.

Pearl Therapeutics

Deerfield

SFJ Pharmaceuticals

AstraZeneca

New Enterprise Associates

At #JPM2024 next week, Nektar’s management team will present on exciting company updates across our #immunology and #immunooncology pipelines. Learn more about us: https://bit.ly/47nZHVe

New preclinical data presented at #ASH23 by our collaborators at NYMC highlight that NKTR-255, in combination with obinutuzumab, expanded NK cells and enhanced antibody-dependent cellular cytotoxicity against rituximab-resistant Burkitt lymphoma cells. Learn more: https://bit.ly/48fE3DO

We’re celebrating Mary Tagliaferri, MD, Nektar’s Chief Medical Officer, who was recently named as one of Inc. Magazine’s 10 Most Eminent Women Leaders in Healthcare 2023. Learn more about Mary and the vital role she plays at Nektar directing clinical strategy, operations and medical affairs: https://bit.ly/3smei5l

At #EADVCongress this week, we presented new and encouraging responder data in late-breaking news oral presentation for Rezpegaldesleukin, our first-in-class selective T-reg therapy, in patients with #atopicdermatitis, also being studied in #alopeciaareata. Full press release: https://bit.ly/3M1sIye

We’re gearing up for #EADVCongress next week, where Nektar will have two presentations for Rezpegaldesleukin, our first-in-class selective regulatory T-cell therapy, being studied in #atopicdermatitis and #alopeciaareata. Additional details: https://bit.ly/3ZDSoXx

COM:NEKTAR